# Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

> **NCT06990529** · PHASE2 · RECRUITING · sponsor: **Pharming Technologies B.V.** · enrollment: 12 (estimated)

## Conditions studied

- PIDs Linked to PI3K

## Interventions

- **DRUG:** Leniolisib

## Key facts

- **NCT ID:** NCT06990529
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2028-09-18
- **Final completion:** 2029-04-13
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990529, "Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06990529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*